settled aclass actionlawsuit for $425 million; the lawsuit claimed that there was insufficient warning about Nexium’s potential to cause kidney damage when used for extended periods of time. AstraZeneca denied wrongdoing, and Nexium continues to be one of the company’s best-selling drugs. ...
MARKET ROUND-UP ; JPM Injects a Critical Note at AstraZenecaANGLO-SWEDISH giant AstraZeneca has high hopes for sales of at least two of its best-selling drugs in the US, but there are those in the City who reckon it has set its sights too high.MICKEY CLARK...
AstraZeneca is currently testing various uses for Seroquel, its best selling anti-psychotic drug. 2008 Seroquel Clinical Trials Given the amount of personal injury complaints about the drug, and the recent approval of Seroquel for bipolar disorder in the U.S., the company may be seeking ...
AstraZeneca hoped to show that patients taking a combination of Iressa and chemo drugs survived four or five months longer than patients taking just chemo drugs. Instead, the tests showed a survival benefit of about two months. The cloudy Iressa data were yanked from ASCO, reportedly, so they...
1943:Astra develops Xylocane, which becomes the world's largest-selling local anesthetic. 1988:Hanakan Mogren appointed CEO of Astra AB. 1993:Zeneca PLC demerged from ICI. 1996:Astra's Losec becomes world's best-selling prescription drug. ...
分享39赞 海角天涯30吧 海角天涯30 【活动】 50 of the best-selling drugs from 2021RT 分享8赞 龙芯吧 格兰登 华尔街日报关于的报道亿万富翁聚会讨论人口过剩 http://chinese.wsj.com/gb/20090528/wrt101244.asp 微软如何扼杀网民隐私保护计划 http://cn.wsj.com/gb/20100803/tec1144 分享14赞 山东药品食品职...
Alexion’s best-selling drug is Soliris, used against a range of rare immune-disorders including paroxysmal nocturnal hemoglobinuria (PNH), which causes anemia and blood clots, and whose revenue rose 3.6% in the first nine months to $3 billion. ...
Alexion's best-selling drug is Soliris, used against a range of rare immune-disorders including paroxysmal nocturnal hemoglobinuria (PNH), which causes anaemia and blood clots, and whose revenue rose 3.6% in the first nine months to $3 billion. ...
In V&I, we saw the first product sales for Beyfortus, which is now approved in the United States following a unanimous vote by the FDA Antimicrobial Drugs Advisory Committee supporting Beyfortus benefit risk profile. AstraZeneca manufactured Beyfortus and then supplies product to Sanofi for ...
and AstraZeneca must find a path to future expansion – perhaps through several smaller acquisitions. The pharma industry faces a global squeeze as governments cut health budgets and big-selling new drugs become rarer and pricier. More consolidation seems inevitable. If AstraZeneca starts to shrink,...